Eli Lilly announced a $3 billion investment to expand its Pleasant Prairie, Wisconsin manufacturing plant, which it acquired earlier this year.

The expansion will increase production of its weight-loss drug Zepbound, diabetes treatments, and other medicines.

This investment, Lilly’s largest outside Indiana, aims to meet soaring demand for drugs like Zepbound and Mounjaro, which faced shortages earlier this year.

Lilly has committed over $23 billion to manufacturing expansions since 2020, CNBC has reported.

The Wisconsin expansion is expected to create 750 new jobs and begin production by late 2025.

Written by B.C. Begley